Digoxin plus immunotherapy and chemo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of digoxin (a heart medication) with serplulimab (an immunotherapy) and chemotherapy as a first treatment for advanced colorectal cancer that is MSS (microsatellite stable). The goal is to see if this combination can help people whose cancer has stopped responding to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with advanced colorectal cancer that has spread and cannot be removed by surgery.
- You have already tried standard chemotherapy (including drugs like fluorouracil, irinotecan, and oxaliplatin) and it stopped working, or you couldn't handle the side effects.
- Your tumor is 'MSS' (microsatellite stable) or 'MSI-L' (low microsatellite instability).
- You have not received immunotherapy before (drugs like PD-1 or PD-L1 inhibitors).
- You are generally in good health (ECOG score 0 or 1) and your major organs (heart, lungs, kidneys, liver) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a combination of three drugs (FOLFOX chemotherapy, fruquintinib, and serplulimab) as a first treatment for people with a specific type of colorectal cancer that cannot be surgically removed. The goal is to shrink the cancer enough to make surgery possible.
This trial tests a combination of chemotherapy (mFOLFOX6) and a targeted antibody (HLX04), followed by immunotherapy (serplulimab) for people with metastatic colorectal cancer that is MSS or pMMR type and cannot be removed by surgery. It is for those who have not had prior chemotherapy with oxaliplatin, immunotherapy, or targeted therapy for their cancer.
This study tests a combination of three drugs—fruquintinib (an anti-angiogenic agent), serplulimab (an immune-boosting antibody), and standard chemotherapy—as a first-line treatment for advanced colorectal cancer with specific genetic mutations. The goal is to see if this combination can help shrink or control tumors better than standard treatment alone.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.